Kanjinti (Intravenous)
Generic name:trastuzumab-anns (intravenous route) [ tras-TOOZ-oo-mab-- anns ]
Medically reviewed by Drugs.com. Last updated on Mar 18, 2022.
Trastuzumab products can result in subclinical and clinical cardiac failure manifesting as CHF and decreased LVEF, with the greatest risk upon concurrent administration with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue trastuzumab-anns in patients receiving adjuvant therapy and withhold trastuzumab for a clinically significant decrease in left ventricular function. Serious and fatal infusion reactions and pulmonary toxicity may occur during or within 24 hours after administration. Discontinue trastuzumab-anns if signs of anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome are noted. Exposure during pregnancy can result in oligohydramnios, in some cases complicated by pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception .
Commonly used brand name(s)
In the U.S.
- Kanjinti
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Trastuzumab
Uses for Kanjinti
Trastuzumab-anns injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or docetaxel and carboplatin) or used alone after a previous treatment with an anthracycline medicine to treat HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer.
Trastuzumab-anns injection is also used to treat HER2-overexpressing metastatic (cancer that has spread) breast cancer in patients who have received one or more cancer treatments. It is also used together with paclitaxel for the first-line treatment of HER2-overexpressing metastatic breast cancer.
Trastuzumab-anns injection is also used together with cisplatin and capecitabine or 5-fluorouracil to treat HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (stomach or esophagus cancer) in patients who have not received treatment previously.
Trastuzumab-anns prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
Trastuzumab-anns is a monoclonal antibody. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal body cells may also be affected by trastuzumab-anns, other effects will also occur. Some of these may be serious and must be reported to your doctor.
This medicine is to be given only by or under the direct supervision of your doctor.
Before using Kanjinti
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had ..
